Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
vTv Therapeutics Inc. (VTVT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/23/2021 |
GN
| vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399 |
| 03/18/2021 |
GN
| vTv Therapeutics Announces Initiation of Study Evaluating TTP399's Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes |
| 03/08/2021 |
GN
| vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference |
| 02/24/2021 |
GN
| vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update |
| 02/23/2021 |
GN
| vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes |
| 02/17/2021 |
GN
| vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis |
| 01/06/2021 |
GN
| vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually |
| 12/15/2020 |
GN
| vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes |
| 12/15/2020 |
GN
| vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio |
| 11/24/2020 |
GN
| vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital |
| 11/05/2020 |
GN
| vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update |
| 11/04/2020 |
GN
| vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study |
| 09/23/2020 |
GN
| vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes |
| 09/15/2020 |
GN
| vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors |
| 08/03/2020 |
GN
| vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update |
| 07/27/2020 |
GN
| vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference |
| 06/13/2020 |
GN
| vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association's Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients |
| 05/27/2020 |
GN
| vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association's 80th Virtual Scientific Sessions |
| 05/22/2020 |
GN
| vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format |
| 05/07/2020 |
GN
| vTv Therapeutics Announces 2020 First Quarter Financial Results and Update |
| 02/20/2020 |
GN
| vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update |
| 12/02/2019 |
GN
| vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference |
| 10/30/2019 |
GN
| vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update |
| 09/18/2019 |
GN
| vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes |
| 09/04/2019 |
GN
| vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference |
| 04/18/2019 |
GN
| Report: Developing Opportunities within Apergy, vTv Therapeutics, Arcimoto, Lipocine, Zealand Pharma A/S, and AquaBounty Technologies — Future Expectations, Projections Moving into 2019 |
| 10/24/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Tabula Rasa Healthcare, Interpublic Group of Companies, Travelport Worldwide, Weight Watchers International, vTv Therapeutics, and Ulta Beauty — New Research Emphasizes Economic Growth |
| 02/16/2018 |
GN
| Detailed Research: Economic Perspectives on OUTFRONT Media, Mylan N.V, Axcelis Technologies, Patterson-UTI Energy, SAExploration, and vTv Therapeutics — What Drives Growth in Today's Competitive Landscape |
| 11/02/2017 |
GN
| Report: Developing Opportunities within Echelon, NII Holdings, ANI Pharmaceuticals, Zion Oil & Gas, vTv Therapeutics, and Sears Holdings – Future Expectations, Projections Moving into 2018 |
|
|